Blood· 2015Q1
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- 1,152citations
- Q1SCImago
- 2015year
Short summary
Azacitidine improved median overall survival by 3.9 months (10.4 vs. 6.5 months) in older patients with newly diagnosed AML (>30% blasts) compared to conventional care regimens (CCRs).
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hematology
HematologyMedicine